within Pharmacolibrary.Drugs.ATC.D;

model D07AC21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 15 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.05 / 1000000,
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Ulobetasol (also known as halobetasol) is a super high-potency topical corticosteroid used for the treatment of corticosteroid-responsive dermatoses, such as plaque psoriasis. It reduces inflammation, itching, and redness. It is typically used as a short-term therapy due to the potential for systemic and local side effects with prolonged use. Ulobetasol is approved for topical application in adults.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic studies reporting quantitative plasma PK parameters or compartmental model of ulobetasol in humans are available; PK profile is estimated based on drug class, route, and FDA label statements.</p><h4>References</h4><ol><li><p>Reddy, V, et al., &amp; Bhutani, T (2020). Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults. <i>Clinical, cosmetic and investigational dermatology</i> 13 391–398. DOI:<a href=&quot;https://doi.org/10.2147/CCID.S252426&quot;>10.2147/CCID.S252426</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32606876/&quot;>https://pubmed.ncbi.nlm.nih.gov/32606876</a></p></li><li><p>Carvajal-Vidal, P, et al., &amp; Calpena, AC (2017). Effect of Different Skin Penetration Promoters in Halobetasol Propionate Permeation and Retention in Human Skin. <i>International journal of molecular sciences</i> 18(11) –. DOI:<a href=&quot;https://doi.org/10.3390/ijms18112475&quot;>10.3390/ijms18112475</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29160818/&quot;>https://pubmed.ncbi.nlm.nih.gov/29160818</a></p></li><li><p>Hecker, D, et al., &amp; Lebwohl, M (2000). In vitro compatibility of tazarotene with other topical treatments of psoriasis. <i>Journal of the American Academy of Dermatology</i> 42(6) 1008–1011. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10827404/&quot;>https://pubmed.ncbi.nlm.nih.gov/10827404</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D07AC21;
